What the data is actually showing is not collapse — it is sorting. The deeper pattern running through today's signals is the gap between what the ecosystem wants to be and what the regulatory and financial infrastructure currently permits. The Patient Choice and Access Act is not failing because of opposition to psychedelics; it is failing because it arrived before the safety architecture that would make its passage politically durable. The ibogaine delay is not a refusal — it is a process gap between congressional intent and agency implementation capacity, one that a well-designed compassionate use protocol with mandatory cardiac monitoring could begin to close. The House Mental Health Caucus hearings projected at 75% probability before end of 2026 represent precisely this: hearings are lower lift than floor votes, they build record, they create the scaffolding that makes legislation viable in the next cycle. What is forming beneath the surface is a regulatory architecture — incomplete, contested, slower than patients need — but forming nonetheless. The highest trajectory genuinely available from here is not a single dramatic breakthrough but the patient, deliberate construction of frameworks: safety amendments that enable legislation, monitoring protocols that enable ibogaine access, hearing records that enable the next bill. The psychedelic field is in the friction phase that precedes institutionalization. The friction is the work.
For veterans living with treatment-resistant PTSD, for patients cycling through failed antidepressant regimens, for families watching someone they love lose ground to opioid dependence — the 12–18 month implementation delays are not abstractions. They are the specific weight of another year. And yet the signal today is not that access is receding; it is that the conditions for durable access are being built under pressure. The veteran advocacy community's nonpartisan discipline — its refusal to let ibogaine become a political football even as the administration's rhetoric creates that risk — is itself a form of infrastructure. What becomes possible, if this holds, is a compassionate use pathway that exists because it was demanded with both urgency and rigor, not despite the friction but through it.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The current is already moving. You are already in it.
81%
Patient Choice Act won't pass Congress before January 2027
Congress is considering a bill that would let patients access psychedelic treatments outside of FDA (the US drug regulator) oversight. It probably won't become law in the next two years because it lacks safety rules that FDA needs, and Congress has too many other priorities. This matters because it affects whether patients can legally get these treatments soon.
→ The Patient Choice Act faces real obstacles and probably won't pass before 2027, so legal psychedelic access remains years away for most people.
Resolves: 2027-01-15 · USA
LEGISLATION
the precise call ▾
Patient Choice and Access Act will not pass in its current form before January 2027. Four agents (fda_reviewer, dea_officer, legislator, journalist) converge on this: no companion safety amendment framework exists, FDA concerns about unregulated access are unaddressed in current draft language, and the legislative calendar is crowded. Two dissenting agents (veteran_advocate, maps_re
77%
DEA will delay any ibogaine research rule by at least 12 months
If Congress passes a law letting researchers study ibogaine (a plant alkaloid with addiction-treatment potential), the DEA (the US drug enforcement agency) controls when it actually happens. The DEA will take at least a year to implement it, even after Congress acts, because that's how the agency has always handled cannabis research exemptions. This delays actual research.
→ The DEA moves on its own schedule, and even congressional approval of ibogaine research won't accelerate their timelines.
Resolves: 2028-06-01 · USA
REGULATION
the precise call ▾
Any NDAA ibogaine research exemption enacted in 2026 will include DEA scheduling review requirements delaying implementation by at least 12 months post-enactment. DEA controls the regulatory implementation timeline regardless of congressional mandate — this is structural, not contingent. Cannabis research exemption history confirms the pattern: Congress authorizes, DEA schedules the scheduling review on its own clock. An ibogaine exemption without a hard DEA
72%
FDA warns against using single anecdotes as proof of psilocybin cures
A few viral stories online claim psilocybin cured someone's Alzheimer's disease. When enough people see these stories, patients and doctors start asking for the treatment, even though one person getting better doesn't prove it works. The FDA (the US drug regulator) will probably issue a formal warning telling doctors and patients not to believe these individual stories. This matters because it protects people from trying unproven treatments.
→ The FDA will likely issue a formal warning against believing individual success stories as proof that psilocybin works for Alzheimer's.
Resolves: 2027-02-28 · USA
REGULATION
the precise call ▾
FDA will issue a formal public communication cautioning against extrapolating single-case psilocybin reports to clinical practice by Q1 2027. Viral single-case 'miracle cure' narratives — particularly in neurodegeneration — have historically triggered FDA MedWatch alerts or public statements within 6–9 months when they generate patient demand or provider confusion. The Alzheimer's psilocybin case report dynamic fits this pattern precisely
74%
Compass Pathways stock drops below $9.50 before September 2026
Compass Pathways, a company developing psilocybin therapy, is showing signs of institutional investors selling off shares. Without major positive news (like successful late-stage trial results), the stock will probably dip below $9.50 at some point in the next nine months. This matters because it signals investor confidence is fragile.
→ Compass stock is likely to dip below $9.50 unless they release positive trial data in the coming months.
Resolves: 2026-09-30 · USA
MARKET
the precise call ▾
CMPS (Compass Pathways) closes below $9.50 on at least one trading day before September 30, 2026, absent Phase 3 data release. A 7.2% single-day drop on no specific catalyst is a technical signal of institutional distribution. Without a hard data catalyst to establish a price floor narrative, the stock is vulnerable to continued drift. Downgrade cycles typically follow distribution phases in small-cap biotech. Condition: if
73%
Ketamine clinics will outperform biotech index through end of 2026
Ketamine is already approved and clinics are already operating profitably. Newer psychedelic companies are still waiting for FDA approval and burning cash on trials. Because ketamine has proven revenue and low regulatory risk, investors should get better returns from ketamine-focused companies than from the broader biotech sector. This matters because it shows where smart money is moving.
→ Ketamine companies will likely outperform the broader biotech sector because they have approved products and actual revenue.
Resolves: 2026-12-31 · USA
MARKET
the precise call ▾
Ketamine infrastructure equities will outperform the XBI (SPDR S&P Biotech ETF) on a total return basis through Q4 2026. Three agents (investor, neuropharmacologist, fda_reviewer) converge: ketamine has approved revenue, clinic infrastructure, and no regulatory overhang — speculative psychedelic biotech has all three risks active simultaneously. The comparison benchmark (XBI) makes this falsifiable and market-anchored